Gordon Saul

Gordon Saul serves as the Executive Director of the Stanford Byers Center for Biodesign and holds the position of Adjunct Professor in BioEngineering at Stanford University since March 2013. Additionally, Gordon is a Board Member at Applaud Medical, Inc., focusing on enhancing treatment methods for kidney stone patients, and serves as a Senior Advisor at Sensyne Health, which specializes in AI-enabled healthcare and drug discovery. Gordon also holds a Board Member position at Drayson Technologies Ltd. Previous roles include Senior Advisor at TauTona Group, Executive-in-Residence at InterWest Partners, and President & CEO of RadioRx, Inc., a pharmaceutical firm dedicated to developing innovative cancer drugs. Gordon's career includes significant experience in business development, having served as Chief Business Officer at Carbylan Therapeutics and Director, SVP of Business Development and Marketing at PowderJect Pharmaceuticals. Gordon holds an MBA from Stanford University and an AB in Engineering from Dartmouth College.